MedPath

Therapeutic Plasma Exchange Adsorption Diafiltration

Not Applicable
Conditions
Septic Shock
Multiple Organ Dysfunction Syndrome
Registration Number
NCT03589378
Lead Sponsor
Shenzhen Second People's Hospital
Brief Summary

The purpose of this study is to evaluate the efficacy of coupled therapeutic plasma exchange adsorption diafiltration (PEAF )for treating septic shock with multiple organ dysfunction syndrome patients in ICU.

Detailed Description

Septic shock with multiple organ dysfunction syndrome (MODS) is a life-threatening clinical condition due to coagulant disorder immunoparalysis to infection. For this reason the extracorporeal therapies for the treatment of septic shock with MODS have become widespread in the ICU and, at the same time, new extracorporeal depurative techniques have been developed for the removal of inflammatory mediators. One of these techniques is therapeutic plasma exchange (TPE) that remove pathologically elevated cytokines and simultaneously to replace protective plasmatic factors. other techniques is coupled plasma-filtration adsorption (CPFA) that uses a sorbent once the separation between plasma and blood has been obtained with a plasma filter. The others is Plasma dialysis filtration(PDF) that can remove inflammatory mediators for patients with multiple organ dysfunction syndrome.The purpose of this study is to evaluate the efficacy of PEAF (coupled therapeutic plasma exchange adsorption diafiltration )for treating septic shock with multiple organ dysfunction syndrome patients in ICU.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
168
Inclusion Criteria
  1. Age, gender: 18-75 years old, male or female;
  2. basic conditions: 20 ≤ APACHE II score ≤ 35 points and 10 ≤ Sequential Organ Failure Assessment(SOFA)≤ 18 points;
  3. septic shock : On the basis of sepsis, after adequate fluid resuscitation, sustained hypotension requires maintenance of vasoactive drugs, mean arterial pressure(MAP)≥ 60 mmHg and Lactate ≥ 2.0 mmol/L; MODS: if the patient's SOFA score is ≥2 points, it means there is organ dysfunction. When the patient has two or more organ dysfunctions, it is MODS.
Exclusion Criteria
  1. can not remove the cause (surgical patients refused surgery, pan drug resistant infection without drug use)
  2. Allergic to AMPLYA™ series
  3. Presence of relative or absolute contraindications to PFA
  4. MODS caused by severe liver disease
  5. malignant tumors
  6. Chronic end-stage disease (predicted to survive no more than one month)
  7. Maternal and possibly pregnant women
  8. participated in drug clinical trials within three months
  9. Admission from an other ICU where the patient remained for more than 24 hours

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
All-cause mortality within 28 days after randomization28 days after randomization

efficacy

Secondary Outcome Measures
NameTimeMethod
free hours of vasoactive drugs from randomization14 days after randomization

efficacy

All-cause mortality within 90 days from randomization90 days from randomization

efficacy

Trial Locations

Locations (12)

Dongguan Fifth People's Hospital (Taiping Hospital)

🇨🇳

Dongguan, Guang Dong, China

Guangzhou General Hospital of Guangzhou Military Region

🇨🇳

Guangzhou, Guang Dong, China

School of Public Health, Southern Medical University

🇨🇳

Guangzhou, Guang Dong, China

Shenzhen Luohu People's hospitial

🇨🇳

Shenzhen, Guang Dong, China

Shenzhen People's Hospital

🇨🇳

Shenzhen, Guang Dong, China

The eighth affiliated hospital, Sun Yat-Sen university

🇨🇳

Shenzhen, Guang Dong, China

Peking University Shenzhen Hospital

🇨🇳

Shenzhen, Guang Dong, China

Shenzhen Sixth People's Hospital (Nanshan Hospital)

🇨🇳

ShenZhen, Guang Dong, China

Affiliated Baoan Hospital of Shenzhen, Southern Medical University (People' hospital of Baoan District)

🇨🇳

Shenzhen, Guang Dong, China

Shenzhen Longgang Central Hospital

🇨🇳

Shenzhen, Guang Dong, China

Scroll for more (2 remaining)
Dongguan Fifth People's Hospital (Taiping Hospital)
🇨🇳Dongguan, Guang Dong, China
Yi Chen, MD Ph.D
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.